Compounded Tirzepatide for Perimenopause: Support During the Transition
In your 40s and fighting stubborn weight gain? Highland Longevity prescribes compounded tirzepatide—a dual GIP/GLP-1 receptor agonist—as part of a physician-supervised plan during the perimenopausal transition. We do not dispense Zepbound or Mounjaro.
How Tirzepatide May Fit a Perimenopause Evaluation
Treatment is individualized to symptoms, medical history, medications, pregnancy potential, contraindications, risks, and goals.
Dual Receptor Activation
Tirzepatide activates both GIP and GLP-1 receptors, addressing multiple metabolic pathways simultaneously. This dual action is particularly valuable when perimenopause disrupts your normal hormonal balance.
Individualized Response
Approved-product trials do not establish the safety, effectiveness, quality, or expected outcomes of Highland's compounded tirzepatide or predict an individual result.
Consistent Appetite Control
The dual mechanism provides more stable appetite suppression despite hormonal fluctuations. When estrogen swings trigger cravings, tirzepatide helps maintain control through multiple pathways.
How Tirzepatide Works During Hormonal Fluctuations
Perimenopause can coincide with changes in symptoms, sleep, activity, body composition, and cardiometabolic risk. The pattern and causes vary and should not be reduced to one hormone or medication mechanism.
Tirzepatide acts at GIP and GLP-1 receptors. Mechanism alone does not establish candidacy, predict an individual response, or show that a compounded formulation is safer or more effective than an FDA-approved option.
Whether treatment is appropriate during perimenopause depends on medical history, contraindications, current medications, pregnancy potential, tolerability, access, risks, and goals.
- GIP receptor activity
- GLP-1 receptor activity
- Metabolic markers monitored when clinically indicated
- Response and adverse effects monitored over time
Comprehensive Care Beyond Medication
Perimenopause affects your entire system—not just your weight. At Highland Longevity, we take a comprehensive approach that addresses multiple factors contributing to perimenopausal weight gain.
- DEXA body composition tracking to monitor fat and muscle
- Hormone testing to understand your specific patterns
- Sleep and stress assessment (often overlooked factors)
- Protein and nutrition guidance for metabolism support
- Optional HRT discussion if symptoms warrant
Sleep, mood, energy, menstrual changes, and weight concerns are followed separately because improvement in one does not guarantee improvement in the others.
How Treatment Is Selected During Perimenopause
Perimenopause-related weight concerns deserve an individualized evaluation. Medication selection depends on medical history, contraindications, current medications, pregnancy potential, tolerability, access, risks, and goals—not a presumed advantage from mechanism alone.
— Dr. Josh Lindsley, DO, DABOM
Compounded Tirzepatide for Perimenopause FAQs
No. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Zepbound or Mounjaro, which are brand-name tirzepatide products manufactured by Eli Lilly and Company. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under physician supervision. Compounded medications are not FDA-approved.
Tirzepatide acts at GIP and GLP-1 receptors. Whether it is appropriate during perimenopause depends on medical history, contraindications, current medications, pregnancy potential, tolerability, access, risks, and goals. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs.
A head-to-head trial of FDA-approved products found a greater average reduction in body weight with tirzepatide at 72 weeks in adults with obesity but without diabetes. That trial did not evaluate Highland's compounded formulations and should not predict an individual result. Highland prescribes compounded tirzepatide and compounded semaglutide; we do not dispense brand-name Zepbound, Mounjaro, Wegovy, or Ozempic.
Menstrual status alone does not determine candidacy. Whether tirzepatide is appropriate depends on medical history, contraindications, current medications, pregnancy potential, contraception, risks, tolerability, and goals.
Weight-loss outcomes vary by medication, dose, duration, adherence, health conditions, and patient. Approved-product trials do not establish expected outcomes for a compounded formulation; no amount or timeline is guaranteed. Highland prescribes compounded tirzepatide; those approved-product trials do not establish expected outcomes for a compounded formulation or an individual patient.
Tirzepatide is not a treatment for hot flashes or perimenopause. Symptoms, hormone-therapy decisions, medication interactions, and weight-management treatment require separate individualized review.
There is no universal deadline or guaranteed easier window. Evaluation can be useful whenever weight, symptoms, function, or cardiometabolic risk warrant attention, with options individualized to the patient.
Compounded medications are generally not covered by health insurance. Insurance coverage typically applies only to brand-name products such as Zepbound or Mounjaro, which Highland Longevity does not dispense.
Serving Fort Worth & Surrounding Communities
Our clinic is conveniently located in the Fort Worth Alliance area, just minutes from communities throughout the DFW metroplex.
Located at 4801 Golden Triangle Blvd Suite 121, Fort Worth, TX 76244
Support During the Transition
Book a free consultation to discuss how compounded tirzepatide's dual-action mechanism can support your goals during perimenopause. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs and does not dispense Zepbound or Mounjaro.
Compounded medication disclaimer: Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Zepbound®, Mounjaro®, or any other brand-name tirzepatide product manufactured by Eli Lilly and Company.
Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under the supervision of our physician. Compounded medications are not FDA-approved. They are permitted under federal law when an FDA-approved product cannot meet the patient's clinical needs, or when the FDA designates a shortage. Your physician will discuss the implications, risks, and benefits of compounded therapy at your consultation.